Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today the acquisition of Swift Biosciences, a pioneer in the development of Next-Generation Sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research. IDT is a leader in developing and manufacturing nucleic acid products for academic and commercial research, agriculture, medical diagnostics, pharmaceutical development, and synthetic biology. Swift develops and commercializes NGS Library Prep Kits that maximize data output, provide comprehensive coverage, and reduce sequencing costs.
“We have been impressed with the Swift products and organizational talent,” said IDT President Trey Martin. “Swift’s research tools are being used for cancer, inherited disease, and other health applications, as well as research in agrigenomics, metagenomics, and the biotech/pharmaceutical industry. Their broad portfolio of library preparation and enrichment products are highly complementary to IDT’s existing NGS product line, giving us an increased ability to provide gold standard offerings to researchers and to be well positioned for future growth.”
“The synergies between IDT and Swift make this acquisition an excellent fit,” commented Nathan Wood, President and CEO of Swift. “Since entering the NGS market in 2013, Swift’s mission has been to provide research tools for long term improvements in the health of individuals and their communities all around the world. IDT has the commercial engine, operational tools, and resources to catalyze these efforts.”
Swift associates and products will transition into IDT while continuing to operate from its existing facilities in Ann Arbor, Michigan. Financial terms of the transaction were not disclosed.
IDT is an operating company within Danaher Corporation’s (NYSE: DHR) Life Sciences platform. For more information, please visit www.idtdna.com.
Follow IDT on Twitter @idtdna for real-time updates and insights.
